Skip to main content

SmartMarker - Clinical Validation of Biomarkers by Smart Data Analyses

Objective

The overall goal of SmartMarker is the development of a commercial infrastructure that allows to transform heterogeneous patient health information, typically stored in multiple clinical and health IT systems, into standardized, comparable, consistent, and queryable data. The ultimate goal of this infrastructure is to conduct retrospective clinical biomarker validation studies and to foster effective treatments to marker-defined patient subgroups. Exploitation of the electronic medical records will allow pragmatic and low cost, but still robust and appropriate analytical retrospective study methods to measure the prognostic and predictive outcome of clinical biomarkers.
SmartMarker will dramatically ease the process of clinical biomarker validation in the cardiology domain. Ischemic heart disease is the leading cause of death in the developed world. The primary biomarker used to identify patients at high risk of sudden death is the ejection fraction. Brain natriuretic peptide is a useful biomarker for predicting the presence of heart failure, risk of readmission and mortality. However, only few biomarkers have been rigorously validated in clinical routine, and few of these markers have been integrated for identifying high risk cohorts in routine clinical practice. This led to a widening implementation gap between recommendations from national and international guidelines and actual routine clinical practice.
With SmartMarker we want to close this gap and achieve best-possible outcomes for the patients. We will validate the link between already existing clinical biomarkers in cardiology that are collected on a daily basis in the clinical routine and pertinent clinical endpoints. Finally, we bring forward effective treatments to marker-defined patient subgroups.

Field of science

  • /natural sciences/computer and information sciences/data science/data analysis
  • /medical and health sciences/clinical medicine/cardiology
  • /medical and health sciences/basic medicine/pharmacology and pharmacy/pharmaceutical drug
  • /social sciences/economics and business/business and management/commerce

Call for proposal

H2020-SMEINST-1-2015
See other projects for this call

Funding Scheme

SME-1 - SME instrument phase 1

Coordinator

Averbis GmbH
Address
Tennenbacher Strasse 11
79106 Freiburg Im Breisgau
Germany
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
EU contribution
€ 50 000